Immunal reconstitution after autologous purified CD+34 cells transplantation in patients with systemic lupus erythematosus
- VernacularTitle:自体纯化CD+34细胞移植治疗系统性红斑狼疮的免疫重建研究
- Author:
Yongqiang WEI
;
Qifa LIU
;
Jing SUN
;
Dan XU
;
Zhengshan YI
;
Ru FENG
;
Fanyi MENG
- Publication Type:Journal Article
- Keywords:
Transplantation,autologous;
CD+34 cells;
Lupus erythematosus,systemic;
Immune reconstitution
- From:
Chinese Journal of Internal Medicine
2008;47(8):650-653
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the variation of immune index in patients with systemic lupus erythematosus (SLE) treated with autologous purified CD+34 cells transplantation and to clarify the relationship with pathogenesis and prognosis. Methods Flow cytometry (FCM) and enzyme linked immunosorbent assay(ELISA) were used to test lymphocyte subsets, C3, C4, CH50, autoantibodies and immunoglobulin for 18 cases of SLE before and after transplantation. Results The results showed that the ratio of all the T cell subsets reduced obviously in early postgraft and recovered gradually in 1 to 3 months after transplantation except CD45 RO+CD+4 cells. The levels of serum C3, C4, CH50 increased significantly after transplantation. No case relapsed within one year after transplantation, but 2 patients relapsed one year after transplantation. The levels of the indexes in the patients with relapse were significantly lower than those in the patients with persistent remission, including C4 in the entire course, CH50 in the 3rd and 12th month after transplantation and CD45 RA+ CD+8 cells in the 6th month after transplantation. However, the ratio of CD45 RO+ CD+4 cells in the first month after transplantation in the patients with relapse was higher than that in the patients with persistent remission. Conclusion Autologous purified CD+34 cells transplantation is effective for treating SLE. Survey of immune indexes before and after transplantation is important to investigate the pathogenesis of SLE. Moreover, these immune indexes can be used to predict therapeutic efficacy of SLE.
